Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by NewToInvesting7on Mar 16, 2022 3:21pm
157 Views
Post# 34519566

RE:RE:RE:It's not Nailoser

RE:RE:RE:It's not NailoserI have to agree, I do not see StageZero disclosing Aristotle sales.

Where I do disagree is potentially seeing an increase in Covid testing revenues for Q4.  It would be nice ot see this, but realistically, there were many other cheaper PCR testing options in the last month or two of 2021.  So unless travel ramped by 200%+ and StageZero saw an equal increase in the demand of the Covid testing, then I would expect a decrease in the Covid testing revenues.


molotov420 wrote: unfortunately we're not even going to be told what Aristotle revenue was....they will lump it with Covid again and call it "Lab Revenue"...should see an increase in revenue though. The last quarter of Covid testing should be pretty busy due to Omicron and hopefully Sobeys brought something. If they sold any Aristotle, revs should be better than Q3


<< Previous
Bullboard Posts
Next >>